Long-term effect of patiromer for hyperkalemia treatment in patients with chronic kidney disease, heart failure, and ejection fraction >40% on RAAS inhibitors

ConclusionPatiromer decreased serum K+ through 52 weeks in patients with hyperkalemia, chronic kidney disease, and heart failure with EF>40%, all of whom were taking RAAS inhibitors. These post-hoc results require prospective evaluation, but suggest that patiromer allows control of hyperkalemia in heart failure patients with EF>40% on RAAS inhibitors.ResultOverall, 55 out of 306 randomized patients had heart failure with EF>40% (100% Caucasian, 75% male, 69% ≥65 years of age). Mean (SD) EF was 48 (7)% and mean (SD) eGFR was 41 (13) mL/min/1.73 m² at baseline. All patients had hypertension (mean BP 155/83 mm Hg). Mean serum K+ was reduced to <5.0 mEq/L at the first post-baseline visit (day 3) through 52 weeks (Table). From baseline to 52 weeks, mean (SE) eGFR increased by 6 (3) mL/min/1.73 m² and mean (SE) SBP/DBP decreased by 22 (3)/ 9 (2) mm Hg. Forty-two (76%) patients reported ≥1 adverse event (AE); hypomagnesemia (9.1%) was the most common AE (none severe). Three patients had serum K+ <3.5 mEq/L.
Source: Heart and Lung: The Journal of Acute and Critical Care - Category: Respiratory Medicine Source Type: research